Navigation Links
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Date:2/15/2008

SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected investors to purchase up to 9,240,307 shares of Cadence's common stock at a purchase price of $5.34 per share pursuant to an effective shelf registration statement.

The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced to 8,056,716 and the gross proceeds may be reduced to $43.0 million pursuant to Nasdaq Marketplace Rule 4350(i)(1)(B) limitations, pending the determination of the applicability of such rule prior to the closing of the offering.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Cadence Pharmaceuticals, Inc., 12481 High Bluff Drive, Suite 200, San Diego, California, Attention: General Counsel, or by calling (858) 436-1400.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... different cell type. Many treatments for specific cancers, such as breast, prostate, or ... treatment is androgen deprivation therapy for advanced prostate cancer. , This therapy ...
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
(Date:8/15/2017)... ... , ... Any expert in stem cell research or stem cell medicine knows ... a century. Despite their essential roles in human health and regenerative medicine, adult ... developed for this purpose also tag other, more abundant, non-stem tissue cells ( See ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):